Atlas Trials

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Clinical trial NCT04941716 · RECRUITING

Trial details

NCT number
NCT04941716
Sponsor
Fred Hutchinson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Start date
2023-05-31
Primary completion
2027-08-10
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.